ESC Premium Access

Effect of sodium-glucose co-transporter 2 inhibitors on left ventricular mass and left atrial volume indices assessed either by cardiovascular magnetic resonance or transthoracic echocardiography

Presentation

About the speaker

Mr Dimitrios Patoulias

Hippokration General Hospital of Thessloniki, Thessaloniki (Greece)
0 follower

124 more presentations in this session

Left atrial volume changes during exercise stress echocardiography in heart failure and hypertrophic cardiomyopathy

Speaker: Doctor C. Prota (Salerno, IT)

Thumbnail

The efficacy of three dimensional echocardiography in assessment of aortic atherosclerotic plaques compared to two dimensional echocardiography

Speaker: Doctor M. Behjati (Isfahan, IR)

Thumbnail

Global longitudinal strain as a predictor of cardiovascular events and mortality in patients with ischemic heart disease and heart failure with preserved/mid-range ejection fraction

Speaker: Mr J. Santos (Viseu, PT)

Thumbnail

Myocardial injury in stress echocardiography: comparison of dobutamine, dipyridamole and dynamic stress echocardiography - single centre study

Speaker: Professor R. Pudil (Prague, CZ)

Thumbnail

Severe aortic stenosis echocardiographic thresholds revisited

Speaker: Doctor S. Schwartzenberg (Petah Tikva, IL)

Thumbnail

Access the full session

Echocardiography ePosters

Speakers: Mr D. Patoulias, Doctor C. Prota, Doctor M. Behjati, Mr J. Santos, Professor R. Pudil...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

24-hour ambulatory blood pressure recordings: when and how.

29 August 2021

ESC Premium Access

Prediction of sudden cardiac death: genetic testing, ECG, and imagingPrediction of sudden cardiac death: genetic testing, ECG, and imaging - Chat Moderator.

29 August 2021

ESC Premium Access

How should I treat my patient with acute heart failure? - Chat Moderator.

27 August 2021

This platform is supported by

logo Novo Nordisk